The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing
Open accessAbstract
Human leukocyte antigen B (HLA-B) is a gene that encodes a cell surface protein involved in presenting antigens to the immune system. The variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in response to carbamazepine treatment. We summarize evidence from the published literature supporting this association and provide recommendations for the use of carbamazepine based on HLA-B genotype (also available on PharmGKB: http://www.pharmgkb.org). The purpose of this article is to provide information to allow the interpretation of clinical HLA-B*15:02 genotype tests so that the results can be used to guide the use of carbamazepine. The guideline provides recommendations for the use of carbamazepine when HLA-B*15:02 genotype results are available. Detailed guidelines regarding the selection of alternative therapies, the use of phenotypic tests, when to conduct genotype testing, and cost-effectiveness analyses are beyond the scope of this document. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines are published and updated periodically on the PharmGKB website at (http://www.pharmgkb.org).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
HLA-B*5701 Screening for Hypersensitivity to Abacavir
Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706135 · Cited by 1,835
A marker for Stevens–Johnson syndrome
Chung, W.-H., Hung, S.-I., Hong, H.-S., Hsih, M.-S., Yang, L.-C., Ho, H.-C., Wu, J.-Y., & Chen, Y.-T. (2004) · Nature · doi:10.1038/428486a · Cited by 1,753
Severe Adverse Cutaneous Reactions to Drugs
Roujeau, J. C., & Stern, R. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311906 · Cited by 1,571
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
Roujeau, J.-C., Kelly, J. P., Naldi, L., Rzany, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332404 · Cited by 1,465
Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Hung, S.-I., Chung, W.-H., Liou, L.-B., Chu, C.-C., Lin, M., Huang, H.-P., Lin, Y.-L., Lan, J.-L., Yang, L.-C., Hong, H.-S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409500102 · Cited by 1,284
A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1
Fellay, J., Shianna, K. V., Ge, D., Colombo, S., Ledergerber, B., Weale, M., Zhang, K., Gumbs, C., Castagna, A., Cossarizza, A., et al. (2007) · Science · doi:10.1126/science.1143767 · Cited by 1,235
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Pharmacogenetics: From Bench to Byte— An Update of Guidelines
Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., Rongen, G. A. P. J. M., van Schaik, R. H. N., Schalekamp, T., Touw, D. J., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.34 · Cited by 1,018
Migueles, S. A., Sabbaghian, M. S., Shupert, W. L., Bettinotti, M. P., Marincola, F. M., Martino, L., Hallahan, C. W., Selig, S. M., Schwartz, D., Sullivan, J., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050567397 · Cited by 995
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
study, F. T. D., Daly, A. K., International SAE Consortium, Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe'er, I., Floratos, A., Daly, M. J., Goldstein, D. B., et al. (2009) · Nature Genetics · doi:10.1038/ng.379 · Cited by 944
Self-citationHLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
McCormack, M., Alfirevic, A., Bourgeois, S., Farrell, J. J., Kasperavičiūtė, D., Carrington, M., Sills, G. J., Marson, T., Jia, X., de Bakker, P. I. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013297 · Cited by 925
Self-citationAberg, J. A., Kaplan, J. E., Libman, H., Emmanuel, P., Anderson, J. R., Stone, V. E., Oleske, J. M., Currier, J. S., & Gallant, J. E. (2009) · Clinical Infectious Diseases · doi:10.1086/605292 · Cited by 837
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L., Spreen, W., Lai, E., Davies, K., Handley, A., Dow, D. J., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08158-8 · Cited by 807
The HLA genomic loci map: expression, interaction, diversity and disease
Shiina, T., Hosomichi, K., Inoko, H., & Kulski, J. K. (2009) · Journal of Human Genetics · doi:10.1038/jhg.2008.5 · Cited by 782
Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan
Chen, P., Lin, J.-J., Lu, C.-S., Ong, C.-T., Hsieh, P. F., Yang, C.-C., Tai, C.-T., Wu, S.-L., Lu, C.-H., Hsu, Y.-C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009717 · Cited by 711
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions
Hung, S.-I., Chung, W.-H., Jee, S.-H., Chen, W.-C., Chang, Y.-T., Lee, W.-R., Hu, S.-L., Wu, M.-T., Chen, G.-S., Wong, T.-W., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000199500.46842.4a · Cited by 680
Lonjou, C., Borot, N., Sekula, P., Ledger, N., Thomas, L., Halevy, S., Naldi, L., Bouwes-Bavinck, J.-N., Sidoroff, A., de Toma, C., et al. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f3ef9c · Cited by 624
Ozeki, T., Mushiroda, T., Yowang, A., Takahashi, A., Kubo, M., Shirakata, Y., Ikezawa, Z., Iijima, M., Shiohara, T., Hashimoto, K., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq537 · Cited by 515
Man, C. B. L., Kwan, P., Baum, L., Yu, E., Lau, K. M., Cheng, A. S. H., & Ng, M. H. L. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01022.x · Cited by 507
Locharernkul, C., Loplumlert, J., Limotai, C., Korkij, W., Desudchit, T., Tongkobpetch, S., Kangwanshiratada, O., Hirankarn, N., Suphapeetiporn, K., & Shotelersuk, V. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01719.x · Cited by 482
Martin, A. M., Nolan, D., Gaudieri, S., Almeida, C. A., Nolan, R., James, I., Carvalho, F., Phillips, E., Christiansen, F. T., Purcell, A. W., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307067101 · Cited by 452
Ferrell, P. B., & McLeod, H. L. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.10.1543 · Cited by 439
Mechanisms of MHC class I‐restricted antigen processing and cross‐presentation
Cresswell, P., Ackerman, A. L., Giodini, A., Peaper, D. R., & Wearsch, P. A. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00316.x · Cited by 435
Saag, M., Balu, R., Phillips, E., Brachman, P., Martorell, C., Burman, W., Stancil, B., Mosteller, M., Brothers, C., Wannamaker, P., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/529382 · Cited by 425
Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells
Nassif, A., Bensussan, A., Boumsell, L., Deniaud, A., Moslehi, H., Wolkenstein, P., Bagot, M., & Roujeau, J.-C. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.07.047 · Cited by 412
Kaniwa, N., Saito, Y., Aihara, M., Matsunaga, K., Tohkin, M., Kurose, K., Sawada, J.-I., Furuya, H., Takahashi, Y., Muramatsu, M., et al. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.11.1617 · Cited by 410
Hetherington, S., McGuirk, S., Powell, G., Cutrell, A., Naderer, O., Spreen, B., Lafon, S., Pearce, G., & Steel, H. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80132-6 · Cited by 406
A marker for Stevens-Johnson syndrome …: ethnicity matters
Lonjou, C., Thomas, L., Borot, N., Ledger, N., de Toma, C., LeLouet, H., Graf, E., Schumacher, M., Hovnanian, A., Mockenhaupt, M., et al. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500356 · Cited by 401
Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy
Sax, P. E., Tierney, C., Collier, A. C., Fischl, M. A., Mollan, K., Peeples, L., Godfrey, C., Jahed, N. C., Myers, L., Katzenstein, D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906768 · Cited by 313
Drug Specific Cytotoxic T-Cells in the Skin Lesions of a Patient with Toxic Epidermal Necrolysis
Nassif, A., Bensussan, A., Bachot, N., Bagot, M., Boumsell, L., Roujeau, J.-C., Dorothée, G., & Mami-Chouaib, F. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.01622.x · Cited by 310
Rauch, A., Nolan, D., Martin, A., McKinnon, E., Almeida, C., & Mallal, S. (2006) · Clinical Infectious Diseases · doi:10.1086/504874 · Cited by 296
Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity
Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K., & Pirmohamed, M. (2004) · Pharmacogenetics · doi:10.1097/00008571-200406000-00002 · Cited by 290
Self-citationHLA-B Locus in Caucasian Patients with Carbamazepine hypersensitivity
Alfirevic, A., Jorgensen, A. L., Williamson, P. R., Chadwick, D. W., Park, B. K., & Pirmohamed, M. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.6.813 · Cited by 264
Self-citationTennis, P., & Stern, R. S. (1997) · Neurology · doi:10.1212/wnl.49.2.542 · Cited by 261
McLean, M. J., & Macdonald, R. L. (1986) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24848-0 · Cited by 245
Hershfield, M. S., Callaghan, J. T., Tassaneeyakul, W., Mushiroda, T., Thorn, C. F., Klein, T. E., & Lee, M. T. M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.209 · Cited by 245
Naisbitt, D. J., Britschgi, M., Wong, G., Farrell, J., Depta, J. P. H., Chadwick, D. W., Pichler, W. J., Pirmohamed, M., & Park, B. K. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.3.732 · Cited by 225
Self-citationMartin, M. A., Klein, T. E., Dong, B. J., Pirmohamed, M., Haas, D. W., & Kroetz, D. L. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.355 · Cited by 201
Self-citationDelayed drug hypersensitivity: models of T‐cell stimulation
Adam, J., Pichler, W. J., & Yerly, D. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03764.x · Cited by 163
Host Determinants of HIV‐1 Control in African Americans
Pelak, K., Goldstein, D. B., Walley, N. M., Fellay, J., Ge, D., Shianna, K. V., Gumbs, C., Gao, X., Maia, J. M., Cronin, K. D., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/651382 · Cited by 161
Genetics and genomics of ankylosing spondylitis
Thomas, G. P., & Brown, M. A. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00852.x · Cited by 159
HLA Genotype and Carbamazepine-Induced Cutaneous Adverse Drug Reactions: A Systematic Review
Yip, V. L. M., Marson, A. G., Jorgensen, A., Pirmohamed, M., & Alfirevic, A. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.189 · Cited by 154
Self-citationBedimo, R., Westfall, A. O., Drechsler, H., Vidiella, G., & Tebas, P. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir269 · Cited by 149
Pharmacogenetics of Drug Hypersensitivity
Phillips, E. J., & Mallal, S. A. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.77 · Cited by 117
Becquemont, L., Alfirevic, A., Amstutz, U., Brauch, H. B., Jacqz-Aigrain, É., Laurent‐Puig, P., Molina‐Vila, M. Á., Niemi, M., Schwab, M. G., Somogyi, A. A., et al. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.147 · Cited by 116
Phenotype Standardization for Immune-Mediated Drug-Induced Skin Injury
Pirmohamed, M., Friedmann, P. S., Molokhia, M., Loke, Y. K., Smith, C. H., Phillips, E., Grenade, L. L., Carleton, B., Papaluca‐Amati, M., Demoly, P. M., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.79 · Cited by 111
Self-citationProspective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience
Waters, L. J., Mandalia, S., Gazzard, B., & Nelson, M. R. (2007) · AIDS · doi:10.1097/qad.0b013e328273bc07 · Cited by 101
PharmGKB summary: carbamazepine pathway
Thorn, C. F., Leckband, S. G., Kelsoe, J. R., Leeder, J. S., Müller, D. J., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328348c6f2 · Cited by 99
Self-citationYoung, B., Squires, K., Patel, P., DeJesus, E., Bellos, N. C., Berger, D., Sutherland‐Phillips, D., Liao, Q., Shaefer, M. S., & Wannamaker, P. G. (2008) · AIDS · doi:10.1097/qad.0b013e32830719aa · Cited by 95
Hughes, A. R., Spreen, W. R., Mosteller, M., Warren, L. L., Lai, E., Brothers, C. H., Cox, C. J., Nelsen, A. J., Hughes, S., Thorborn, D. E., et al. (2008) · The Pharmacogenomics Journal · doi:10.1038/tpj.2008.3 · Cited by 89
National marrow donor program HLA-matching guidelines for unrelated marrow transplants
Hurley, C. K., Lowe, L. A. B., Logan, B. R., Karanes, C., Anasetti, C., Weisdorf, D. J., & Confer, D. L. (2003) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2003.08.009 · Cited by 86
Immune responses to abacavir in antigen-presenting cells from hypersensitive patients
Martin, A. M., Almeida, C.-A. M., Cameron, P. U., Purcell, A. W., Nolan, D. A., JAMES, I. R., McCluskey, J., Phillips, E. J., LANDAY, A. L., & Mallal, S. A. (2007) · AIDS · doi:10.1097/qad.0b013e3280119579 · Cited by 65
He, N., Min, F., Shi, Y., Guo, J., Liu, X., Li, B.-M., Zhou, J.-H., Ou, Y.-M., Liao, J., & Liao, W. (2012) · Seizure · doi:10.1016/j.seizure.2012.06.014 · Cited by 47
Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions
Locharernkul, C., Shotelersuk, V., & Hirankarn, N. (2011) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2010.12.054 · Cited by 45
Cytokine Profiling in Abacavir Hypersensitivity Patients
Almeida, C.-A. M., Martin, A. M., Nolan, D. A., Lucas, A., Cameron, P. U., JAMES, I. R., Phillips, E. J., & Mallal, S. A. (2008) · Antiviral Therapy · doi:10.1177/135965350801300202 · Cited by 25
Cited by
Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers
Dunnenberger, H. M., Crews, K. R., Hoffman, J. M., Caudle, K. E., Broeckel, U., Howard, S. C., Hunkler, R. J., Klein, T. E., Evans, W. E., & Relling, M. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124835 · Cited by 511
Self-citationHicks, J. K., Swen, J. J., Thorn, C. F., Sangkuhl, K., Kharasch, E. D., Ellingrod, V. L., Skaar, T. C., Müller, D. J., Gaedigk, A., & Stingl, J. C. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.2 · Cited by 453
Self-citationCaudle, K., Klein, T., Hoffman, J., Muller, D., Whirl-Carrillo, M., Gong, L., McDonagh, E., Sangkuhl, K., Thorn, C., Schwab, M., et al. (2014) · Current Drug Metabolism · doi:10.2174/1389200215666140130124910 · Cited by 446
Self-citationClinically Actionable Genotypes Among 10,000 Patients With Preemptive Pharmacogenomic Testing
Van Driest, S., Shi, Y., Bowton, E., Schildcrout, J., Peterson, J., Pulley, J., Denny, J., & Roden, D. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.229 · Cited by 334
Phillips, E. J., Sukasem, C., Whirl‐Carrillo, M., Müller, D. J., Dunnenberger, H. M., Chantratita, W., Goldspiel, B., Chen, Y., Carleton, B. C., George, A. L., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1004 · Cited by 328
Self-citation
Metadata
- Authors
- Leckband, S. G., Kelsoe, J. R., Dunnenberger, H. M., George, A. L., Tran, E., Berger, R., Müller, D. J., Whirl-Carrillo, M., Caudle, K. E., & Pirmohamed, M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2013-05-21
- Volume
- 94
- Issue
- 3
- Pages
- 324-328
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1971946342
- Cited by
- 335
- References
- 58
- FWCI
- 27.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.